TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lessened its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 27.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 82,752 shares of the biopharmaceutical company's stock after selling 30,931 shares during the quarter. State of New Jersey Common Pension Fund D owned approximately 0.05% of TG Therapeutics worth $1,936,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Swiss National Bank increased its position in shares of TG Therapeutics by 0.5% in the first quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company's stock valued at $4,321,000 after buying an additional 1,500 shares in the last quarter. Sei Investments Co. purchased a new stake in TG Therapeutics in the 1st quarter worth $591,000. Russell Investments Group Ltd. increased its holdings in TG Therapeutics by 133.5% in the 1st quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company's stock worth $796,000 after acquiring an additional 29,923 shares in the last quarter. ProShare Advisors LLC raised its position in TG Therapeutics by 8.5% during the first quarter. ProShare Advisors LLC now owns 24,914 shares of the biopharmaceutical company's stock worth $379,000 after acquiring an additional 1,961 shares during the period. Finally, State Board of Administration of Florida Retirement System lifted its holdings in TG Therapeutics by 10.5% during the first quarter. State Board of Administration of Florida Retirement System now owns 43,283 shares of the biopharmaceutical company's stock valued at $651,000 after purchasing an additional 4,120 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Stock Up 0.2 %

TGTX stock traded up $0.07 during midday trading on Monday, reaching $29.61. 4,313,209 shares of the company were exchanged, compared to its average volume of 3,711,314. The company has a market cap of $4.61 billion, a price-to-earnings ratio of -296.10 and a beta of 2.19. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a 1-year low of $11.86 and a 1-year high of $36.50. The stock's 50-day simple moving average is $24.86 and its 200 day simple moving average is $21.25.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm's revenue for the quarter was down 49.4% compared to the same quarter last year. During the same period last year, the company earned $0.73 earnings per share. On average, equities analysts forecast that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Insider Transactions at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.50% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on TGTX shares. HC Wainwright boosted their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. The Goldman Sachs Group boosted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. TD Cowen initiated coverage on TG Therapeutics in a research report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price on the stock. Finally, B. Riley boosted their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $37.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.